ArriVent BioPharma, Inc. Common Stock
AVBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $32 | $28 | $61 | $20 |
| G&A Expenses | $6 | $6 | $5 | $4 |
| SG&A Expenses | $6 | $6 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $38 | $34 | $67 | $24 |
| Operating Income | -$38 | -$34 | -$67 | -$24 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $2 | $2 | $3 |
| Pre-Tax Income | -$35 | -$31 | -$64 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$35 | -$31 | -$64 | -$21 |
| % Margin | – | – | – | – |
| EPS | -0.83 | -0.9 | -1.9 | -0.61 |
| % Growth | 7.8% | 52.6% | -211.5% | – |
| EPS Diluted | -0.83 | -0.9 | -1.9 | -0.61 |
| Weighted Avg Shares Out | 42 | 35 | 34 | 34 |
| Weighted Avg Shares Out Dil | 42 | 35 | 34 | 34 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $2 | $2 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$35 | -$31 | -$67 | -$24 |
| % Margin | – | – | – | – |